Nurix Therapeutics, Inc. (NRIX)

US — Healthcare Sector
Peers: FHTX  STTK  GLUE  KYMR  CCCC  ARVN  ELYM  PRLD  RLAY  STOK  PLRX  BDTX  NKTX  LYEL  GBIO  SANA 

Automate Your Wheel Strategy on NRIX

With Tiblio's Option Bot, you can configure your own wheel strategy including NRIX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NRIX
  • Rev/Share 0.6752
  • Book/Share 5.7553
  • PB 1.847
  • Debt/Equity 0.0554
  • CurrentRatio 6.2642
  • ROIC -0.4342

 

  • MktCap 810384428.0
  • FreeCF/Share -2.4125
  • PFCF -4.0199
  • PE -4.2622
  • Debt/Assets 0.0433
  • DivYield 0
  • ROE -0.4749

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation NRIX Leerink Partners -- Market Perform -- $16 March 17, 2025
Initiation NRIX BTIG Research -- Buy -- $35 Dec. 10, 2024
Initiation NRIX BMO Capital Markets -- Outperform -- $35 Dec. 6, 2024
Initiation NRIX Jefferies -- Buy -- $41 Oct. 11, 2024
Resumed NRIX Robert W. Baird -- Outperform -- $26 Sept. 6, 2024

News

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma
NRIX
Published: May 14, 2025 by: GlobeNewsWire
Sentiment: Neutral

SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that data from the Company's ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia will be presented at two major upcoming scientific conferences.

Read More
image for news Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
NRIX
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour

Read More
image for news Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
Nurix Therapeutics, Inc. (NRIX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
NRIX
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Negative

Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Nurix Therapeutics, Inc. (NRIX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NRIX
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral

SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on February 11, 2025, the company granted inducement awards to nine new employees. The grants were made pursuant to Nurix's 2024 Equity Inducement Plan as an inducement material to the employees' acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix's Board of Directors in …

Read More
image for news Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

About Nurix Therapeutics, Inc. (NRIX)

  • IPO Date 2020-07-24
  • Website https://www.nurixtx.com
  • Industry Biotechnology
  • CEO Dr. Arthur T. Sands M.D., Ph.D.
  • Employees 286

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.